Novartis has abandoned development of its drug to treat presbyopia, a common age-related loss of near distance vision, after it failed a phase 2b trial. The eyedrop formulation of
AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on near objects.
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.